Aventis Pharma S.a.

Sanofi-a Ventis Deutschland Gmbh

Sanofi

Ingrid Sassoon

Hans Matter

David William Will

Anke Steinmetz

Karl Schoenafinger

Swen Hoelder

Christine Delaisi

Gunter Muller

Cecile Combeau

Daniel J Tavares

Alain Commercon

Herve Bouchard

Vincent Mikol

Martin Bossart

Hervé Bouchard

Fabienne Parker

Claudia Fromond

Didier Benard

Cécile Combeau

Thomas Rooney

Karl Schönafinger

Franck Halley

Bernard Baudoin

Gilles Tiraboschi

Günter Müller

Thorsten Naumann

Swen Hölder

Günther Müller

Dominique Le Suisse

The present disclosure relates to an antibody or an epitope-binding fragment thereof that specifically binds to an EphA2 receptor. It further relates to a conjugate comprising a cytotoxic agent which is covalently bound to the antibody and a method for preparing such a conjugate.

Antibodies that specifically bind to the EphA2 receptor

Disclosed are compounds of Formula I wherein X is and R, R, A, B, D, E, Rare as defined herein useful for treating cancers.

Pyridazinone kinase inhibitors

Disclosed are compounds of the general formula (I), where the definition of the substituents A, B, D, E, Rand Rare detailed in the description, and the physiologically tolerated salts thereof, a process for the preparation of these compounds and their use as pharmaceuticals.  These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2).

4-benzimidazol-2-ylpyridazin-3-one derivatives

Disclosed are compounds according to the general formula (I), where the definitions of the substituents X, Rand Rare detailed in the description, as well as their physiologically acceptable salts and solvate, methods for producing these compounds and their use as pharmaceuticals.  These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2).

Pyridazinone derivatives

The present invention relates to novel pyridazinone derivatives of the general formula (I) wherein 

Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them

Growing community of inventors

Villejuif, France

Ingrid Sassoon